DLT pricing and access tiers
Two routes into the platform, set by company stage and how your team intends to use the data.
Already licensed by Top 10 Big Pharmas
EVERY SUBSCRIPTION INCLUDES
- Standard platform access with AI co-pilot
- All company, asset, target, patent and financing records
- Named seats on an annual or quarterly subscription
TIER 1
Biotech
Pricing on request
Priced per named seat, on an annual or quarterly subscription
- Standard platform access with AI co-pilot
- Yearly subscription, or a 3-month subscription renewable quarterly
- Standard license on fixed terms
- Purchase online or via invoice/bank transfer
Founder / BD lead, BD / Corp Dev
TIER 2
Big Pharma
Custom
Dependent on goals, departmental usage and API integration
- Wider platform access, API + dedicated account manager
- Discovery call → custom set-up
- Variable license, subject to contract requirements
- Annualized contract
BD, Head of R&D, CVC
INVESTORS: VC, CVC, PE
DLT is not available to investors. We are open to partnering with the right firm.
TIERS IN FULL
Which tier you sit in, and what that means
Tiers follow capitalization rather than headcount, because it tracks where a team sits in the licensing cycle.
SWIPE TO COMPARE →
| SME Pharma / Biotech | Big Pharma | Investors: VC, CVC, PE | |
|---|---|---|---|
| Capitalization |
<$100M raised to date: Pre-clinical/Phase I, Seed–Series B (typically micro/nano-cap if public)
>$100M raised to date: Late-stage clinical/ commercial (typically small-to-mid-cap if public)
|
Significant, revenue-generating (self-funded R&D from cash, acquisitive) | >$300M AUM |
| DLT buying motive |
Competitive intelligence, fundraising insights, identify Mid-size biotechs (within DLT) to out-license to and share R&D
Competitive intelligence, fundraising insights, identify small biotechs (within DLT) to in-license to and partner on R&D
|
Identify clinically advancing assets from small and medium sized biotechs to in-license, acquire or invest into | Deal sourcing, automated DD workflows, portfolio development, competitive intelligence, market funding insights |
| Users | Founder/BD lead, BD/Corp Dev | BD, Head of R&D, CVC | GP, LP, DD team |
| Access model | Yearly subscription, or 3-month subscription renewable quarterly | Discovery call → custom set-up |
DLT is not available to investors.
We are open to partnering with the right firm.
Book a discovery
call
|
| License | Standard | Variable | |
| Terms | Fixed, purchase via invoice/bank transfer | Subject to contract requirements | |
| What’s included | Standard platform access with AI co-pilot | Wider platform access, API + dedicated account manager | |
| Billing cadence | Annual, or quarterly | Annualized contract | |
| Pricing | Quoted per named seat on request, annual or quarterly | Dependent on goals, departmental usage and API integration | |
| Next step | Book a discovery call | Book a discovery call |
WHERE DLT SITS
How DLT fits into your longevity data agenda
DLT is the only intelligence platform built specifically for longevity (Gerotherapeutic) drug development: tomorrow’s preventive and regenerative therapies. DLT pairs deep scientific and clinical rigor with a longevity-only focus that other incumbents don’t offer.
Citeline and Clarivate (Cortellis)
The gold standard for clinical intelligence and curated life-science data — we recognize this; but they’re built for every therapeutic area. Neither maps assets to pipeline-in-a-pill longevity potential the way DLT does.
GlobalData
Offers broad, easy-to-navigate life-science intelligence — but that breadth comes at the cost of depth on the SMID biotech science that BD teams and investors actually need to act on.
PitchBook
Unmatched for private-market deal and cap-table data, but it covers every industry, with minimal clinical data and no target-biology layer. This is why DLT pulls key financial data directly from PitchBook via API.